PO.MCB08.04 · 分子与细胞生物学

Massively parallel installation and evaluation of cancer coding mutations

海报缩略图:Massively parallel installation and evaluation of cancer coding mutations
编号 5936 展板 24 时间 4/21 02:00–05:00 区域 Section 21 主讲 MARCUS KELLY
分会场 Genetic and Transcriptomic Dissection of Cancer Evolution
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Xiaoyu Zhao1, Isabella Panagiotou1, Rachel Collier1, Catalina Fogg1, Katherine Licon1, John J. Y. Lee1, Dylan Fong1, Jing Chen1, Paulina Rios2, Ondine Atwa2, Samuel I. Gould2, Ingoo Lee1, Jiahao Gao1, Francisco J. Sánchez-Rivera2, MARCUS R. KELLY1, Trey Ideker1

1Medicine, University of California San Diego School of Medicine, La Jolla, CA,2Koch Inst. for Integrative Cancer Research at MIT, Cambridge, MA

摘要 Abstract

Most cancer coding mutations are of unknown function, limiting their biological and therapeutic interpretation. While prime editing enables precise genomic alterations, mutations often reside in sequence contexts unfavorable to current prime-editing guide RNA (pegRNA) designs. Here we develop CodonPrime, a prime-editing framework that exploits codon degeneracy surrounding a mutation site to substantially expand its targeting set of pegRNAs. We use this approach to screen ~2500 coding mutations spanning 298 cancer genes, yielding a 9.2-fold increase in amino-acid editing efficiency over conventional prime editing. Approximately 10% of coding mutations enhance cell growth, recovering known oncogenic hotspots and revealing oncogenic potential for previously uncharacterized mutations (e.g. HNF1A R272C ). Our analysis uncovers dominant effects in paralogous genes (e.g. RHOBTB1/2) and organization of mutant phenotypes in pathways (e.g. PI3K-MTOR signaling). We formulate a general-purpose transformer for design of CodonPrime pegRNAs, enabling scalable interrogation of human coding variants.
利益披露 Disclosure
X. Zhao, None.. I. Panagiotou, None.. R. Collier, None.. C. Fogg, None.. K. Licon, None.. J. J. Y. Lee, None.. D. Fong, None.. J. Chen, None.. P. Rios, None.. O. Atwa, None.. S. I. Gould, None.. I. Lee, None.. J. Gao, None.. M. R. Kelly, None. T. Ideker, Data4Cure g., Board of Directors, non-salaried role), Other Business Ownership. Serinus Biosciences g., Board of Directors, non-salaried role), Other Business Ownership. Eikon Therapeutics Independent Contractor, Other Securities. Ideaya Biosciences Independent Contractor, Other Securities.

在会议检索中打开